Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Target for COVID-19.

ACE2 AXL COVID19 SARS-CoV-2 TIM-1 TMPRSS2 apoptotic mimicry bemcentinib phosphatidylserine receptor viral entry

Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
24 Jun 2021
Historique:
pubmed: 24 6 2021
medline: 24 6 2021
entrez: 23 6 2021
Statut: epublish

Résumé

Phosphatidylserine (PS) receptors are PS binding proteins that mediate uptake of apoptotic bodies. Many enveloped viruses utilize this PS/PS receptor mechanism to adhere to and internalize into the endosomal compartment of cells and this is termed apoptotic mimicry. For viruses that have a mechanism(s) of endosomal escape, apoptotic mimicry is a productive route of virus entry. We evaluated if PS receptors serve as cell surface receptors for SARS-CoV-2 and found that the PS receptors, AXL, TIM-1 and TIM-4, facilitated virus infection when low concentrations of the SARS-CoV-2 cognate receptor, ACE2, was present. Consistent with the established mechanism of PS receptor utilization by other viruses, PS liposomes competed with SARS-CoV-2 for binding and entry. We demonstrated that this PS receptor enhances SARS-CoV-2 binding to and infection of an array of human lung cell lines and is an under-appreciated but potentially important host factor facilitating SARS-CoV-2 entry.

Identifiants

pubmed: 34159331
doi: 10.1101/2021.06.15.448419
pmc: PMC8219095
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : U54 CA260560
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007511
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007337
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI134733
Pays : United States

Commentaires et corrections

Type : UpdateIn

Auteurs

Dana Bohan (D)

Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.

Hanora Van Ert (HV)

Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.

Natalie Ruggio (N)

Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.

Kai J Rogers (KJ)

Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.

Mohammad Badreddine (M)

Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.

José A Aguilar Briseño (JA)

Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.

Roberth Anthony Rojas Chavez (RA)

Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.

Boning Gao (B)

Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX.

Tomasz Stokowy (T)

Department of Biomedicine, University of Bergen, Bergen Norway.

Eleni Christakou (E)

Department of Biomedicine, University of Bergen, Bergen Norway.
BerGenBio ASA, Bergen, Norway.

David Micklem (D)

BerGenBio ASA, Bergen, Norway.

Gro Gausdal (G)

BerGenBio ASA, Bergen, Norway.

Hillel Haim (H)

Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.

John Minna (J)

Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX.

James B Lorens (JB)

Department of Biomedicine, University of Bergen, Bergen Norway.

Wendy Maury (W)

Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.

Classifications MeSH